

Lymphocytes (1000/ $\mu$ L)	1000 (665-1530)	1540 (1235-2135)	845 (610-1257)	<b>&lt;0.001</b>
Hb (g/dL)	13.1 (12.0-13.9)	13.5 (12.6-13.9)	13.1 (11.9-13.8)	0.449
Platelets (1000/ $\mu$ L)	211.5 (160-297.8)	262.5 (203.5-298.8)	176.5 (147-284.3)	0.094
INR (%)	1 (1-1.1)	1 (1-1.1)	1 (1-1.2)	0.289
PTT (s)	24 (22-27)	24 (23-27)	24 (22-27)	0.514
D-Dimer ( $\mu$ g/dL)	0.8 (0.6-1.8)	0.31 (0.31-0.31)	0.9 (0.6-1.8)	0.310
Creatinine (mg/dL)	0.8 (0.7-1.1)	0.8 (0.6-0.9)	0.9 (0.7-1.3)	0.100
GFR-MDRD (ml/m <sup>2</sup> )	79.8 (52.8-101.8)		79.8 (52.8-101.8)	
Sodium (mmol/L)	139 (136-140)	140 (139-141)	137 (134.5-139)	<b>&lt;0.001</b>
CRP (mg/dL)	1.4 (0.3-6.3)	0.2 (0.03-1)	3.1 (1.3-11.2)	<b>&lt;0.001</b>
PCT (ng/mL)	0.1 (0.1-0.2)		0.1 (0.1-0.2)	
IL-6	24.3 (8.7-34.5)		24.3 (8.7-34.5)	
hs TNI (ng/dL)	8 (3.8-18.5)	5 (3.3-7.8)	10.5 (5.3-22)	<b>0.026</b>
NT-pro-BNP (ng/L)	410 (121-1349.3)		519 (128.8-1487.5)	0.144
CK (U/L)	110.5 (65.3-185.5)	84.5 (55-132)	121.5 (66.3-203.3)	0.094
AST (U/L)	32 (17-46)	17 (12.5-21)	41 (21-54)	<b>&lt;0.001</b>
ALT (U/L)	24 (16.3-39)	19 (14.3-32)	30.5 (19-41.8)	<b>0.042</b>
LDH (U/L)	225 (191-290)	195 (172.3-209.3)	264 (218-361)	<b>&lt;0.001</b>
HbA1c (%)	6.1 (5.8-6.5)	5.9 (5.5-6.0)	6.3 (5.8-6.5)	<b>0.011</b>
Concomitant cardiac medication at study entry				
Oral anticoagulation	11 (19.3)	6 (30)	5 (13.5)	0.215
ACE-I or ARB	36 (63.2)	13 (65)	23 (62.2)	0.563
Diuretics	15 (26.3)	3 (15)	12 (32.4)	0.147
Calcium channel blockers	12 (21.1)	5 (25)	7 (12.8)	0.594
Beta blockers	23 (40.4)	6 (30)	17 (18.9)	0.263
Statins	29 (50.9)	10 (50)	19 (51.4)	0.992
ASA	23 (40.1)	10 (50)	13 (35.1)	0.238
P2Y12-Inhibitor	5 (8.8)	4 (20)	1 (2.7)	0.165